-
Posted by
Two Blokes Sat at 8:00 AM -
Filed in
Stock
-
1 view
Hims surpassed 2.4 million subscribers with 95% recurring revenue and over 85% retention, driving 111% YoY revenue growth. Average monthly revenue per subscriber rose 50% YoY, showing strong monetization through personalization, bundling, and chronic care expansion. Despite Novo deal fallout, Hims continues scaling GLP-1 offerings and accelerating proprietary semaglutide development amid regulatory scrutiny.
